NEW YORK, NY / ACCESSWIRE / November 23, 2020 / Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the court. Further details about the cases can be found at the links provided. There is no cost or obligation to you.
PT Shareholders Click Here: https://www.zlk.com/pslra-1/pintec-technology-holdings-limited-loss-form?prid=11127&wire=1
LVS Shareholders Click Here: https://www.zlk.com/pslra-1/las-vegas-sands-corp-loss-submission-form?prid=11127&wire=1
ZSAN Shareholders Click Here: https://www.zlk.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=11127&wire=1
* ADDITIONAL INFORMATION BELOW *
Pintec Technology Holdings Limited (NASDAQ:PT)
This lawsuit is on behalf of shareholders who purchased PT securities pursuant and/or traceable to the registration statement and prospectus issued in connection with the Company's October 2018 initial public offering.
Lead Plaintiff Deadline : November 30, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/pintec-technology-holdings-limited-loss-form?prid=11127&wire=1
According to the filed complaint, (1) the Company erroneously recorded revenue earned from certain technical service fee on a net basis, rather than a gross basis; (2) there were material weaknesses in Pintec's internal control over financial reporting related to cash advances outside the normal course of business to Jimu Group, a related party, and to a non-routine loan financing transaction with a third-party entity, Plutux Labs; (3) as a result of the foregoing, the Company's financial results for fiscal 2017 and 2018 had been misstated; and (4) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects, were materially misleading and/or lacked a reasonable basis.
Las Vegas Sands Corp. (NYSE:LVS)
LVS Lawsuit on behalf of: investors who purchased February 27, 2016 - September 15, 2020
Lead Plaintiff Deadline : December 21, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/las-vegas-sands-corp-loss-submission-form?prid=11127&wire=1
According to the filed complaint, during the class period, Las Vegas Sands Corp. made materially false and/or misleading statements and/or failed to disclose that: (i) weaknesses existed in Marina Bay Sands' casino control measures pertaining to fund transfers; (ii) the Marina Bay Sands' casino was consequently prone to illicit fund transfers that implicated, among other issues, the transfer of customer funds to unauthorized persons and potential breaches in the Company's anti-money laundering procedures; (iii) the foregoing foreseeably increased the risk of litigation against the Company, as well as investigation and increased oversight by regulatory authorities; (iv) Las Vegas Sands had inadequate disclosure controls and procedures; (v) consequently, all the foregoing issues were untimely disclosed; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.
Zosano Pharma Corporation (NASDAQ:ZSAN)
ZSAN Lawsuit on behalf of: investors who purchased February 13, 2017 - September 30, 2020
Lead Plaintiff Deadline : December 28, 2020
TO LEARN MORE, VISIT: https://www.zlk.com/pslra-1/zosano-pharma-corporation-loss-submission-form?prid=11127&wire=1
According to the filed complaint, during the class period, Zosano Pharma Corporation made materially false and/or misleading statements and/or failed to disclose that: (1) the Company's clinical results reflected differences in zolmitriptan exposures observed between subjects receiving different lots; (2) pharmocokinetic studies submitted in connection with the Company's New Drug Application included patients exhibiting unexpected high plasma concentrations of zolmitriptan; (3) as a result of the foregoing differences among patient results, the U.S. Food and Drug Administration was reasonably likely to require further studies to support regulatory approval of the Company's lead product candidate, Qtrypta; (4) as a result, regulatory approval of Qtrypta was reasonably likely to be delayed; and (5) as a result of the foregoing, Defendants' public statements were materially false and misleading at all relevant times.
You have until the lead plaintiff deadlines to request that the court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
[email protected]
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com
SOURCE: Levi & Korsinsky, LLP